Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
17-33127A
Ministerstvo Zdravotnictví Ceské Republiky - International
PubMed
31025138
DOI
10.1007/s00296-019-04301-z
PII: 10.1007/s00296-019-04301-z
Knihovny.cz E-zdroje
- Klíčová slova
- Axial spondyloarthritis, Disease activity, Radiographic damage, Visfatin,
- MeSH
- bederní obratle diagnostické zobrazování MeSH
- cytokiny krev MeSH
- dospělí MeSH
- krční obratle diagnostické zobrazování MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- nikotinamidfosforibosyltransferasa krev MeSH
- páteř diagnostické zobrazování MeSH
- průřezové studie MeSH
- sakroiliakální kloub diagnostické zobrazování MeSH
- spondylartropatie krev diagnostické zobrazování patofyziologie MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- cytokiny MeSH
- nicotinamide phosphoribosyltransferase, human MeSH Prohlížeč
- nikotinamidfosforibosyltransferasa MeSH
The purpose of this cross-sectional study was to assess the visfatin levels in patients with axial spondyloarthritis (axSpA) and to investigate the association between visfatin, disease activity and radiographic spinal damage. Serum visfatin levels were determined by enzyme-linked immunosorbent assay in 64 patients with axSpA (46 with radiographic axSpA (r-axSpA) and 18 with non-radiographic axSpA (nr-axSpA)) and 61 age-/sex-matched healthy individuals. Patients with r-axSpA were further divided into two subsets based on radiographic spinal damage using modified Stoke Ankylosing Spondylitis Spine Score (mSASSS = 0 and mSASSS ≥ 1). The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity. C-reactive protein (CRP) levels and human leukocyte antigen (HLA)-B27 were determined. Visfatin levels were significantly higher in patients with axSpA and in the subgroup of patients with r-axSpA than in healthy individuals (p = 0.010 and p = 0.005, respectively), with no difference between patients with r-axSpA and with nr-axSpA. In general, disease activity was high (mean BASDAI 5.01) and was moderately correlated with visfatin levels (r = 0.585; p = 0.011) in patients with nr-axSpA. Visfatin levels correlated with mSASSS (r = 0.281; p = 0.026) and were significantly higher in axSpA patients with mSASSS ≥ 1 than in those with mSASSS = 0 (p = 0.025). Our study showed that circulating visfatin levels are elevated in axSpA patients, may be associated with disease activity in early phase of the disease and with the degree of radiographic spinal involvement.
Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic
Institute of Rheumatology Na Slupi 4 12850 Prague 2 Czech Republic
Zobrazit více v PubMed
Diabetes Res Clin Pract. 2011 Feb;91(2):154-8 PubMed
Dis Markers. 2017;2017:7574147 PubMed
Mutat Res. 2010 Aug 7;690(1-2):95-101 PubMed
Lancet. 2017 Jul 1;390(10089):73-84 PubMed
Ann Rheum Dis. 2009 Jun;68(6):777-83 PubMed
Ann Rheum Dis. 2014 Dec;73(12):2137-43 PubMed
Arthritis Rheum. 2007 Sep;56(9):2829-39 PubMed
Nat Rev Immunol. 2011 Feb;11(2):85-97 PubMed
Arthritis Res Ther. 2017 Jun 15;19(1):140 PubMed
RMD Open. 2015 Aug 15;1(Suppl 1):e000053 PubMed
Autoimmun Rev. 2016 Jun;15(6):501-9 PubMed
Clin Rheumatol. 2012 Jan;31(1):67-71 PubMed
Nat Rev Rheumatol. 2016 May;12(5):296-302 PubMed
Clin Exp Rheumatol. 2013 Jul-Aug;31(4):538-45 PubMed
Clin Pharmacol Ther. 2001 Mar;69(3):89-95 PubMed
Calcif Tissue Int. 2007 Mar;80(3):201-10 PubMed
J Leukoc Biol. 2008 Apr;83(4):804-16 PubMed
RMD Open. 2017 Jan 11;3(1):e000319 PubMed
Mol Med Rep. 2017 Feb;15(2):784-792 PubMed
J Immunol. 2007 Feb 1;178(3):1748-58 PubMed
Arthritis Rheumatol. 2015 Mar;67(3):678-85 PubMed
Mol Cell Biol. 1994 Feb;14(2):1431-7 PubMed
Arthritis Rheum. 1984 Apr;27(4):361-8 PubMed
Eur J Clin Invest. 2015 Jan;45(1):81-6 PubMed
